PriceTargets.com logo

Daiichi Sankyo - DSNKY Stock Price Target and Predictions

  • Consensus Rating: Reduce
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$30.50 As of 04/24/2024 01:00 AM ET
▲ +0.21 (0.69%)

This chart shows the closing price for DSNKY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Daiichi Sankyo Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DSNKY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DSNKY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Daiichi Sankyo in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $30.50.

This chart shows the closing price for DSNKY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 2 polled investment analysts is to reduce stock in Daiichi Sankyo. This Reduce consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/25/2023Jefferies Financial GroupDowngradeBuy ➝ Hold
5/23/2023Sanford C. BernsteinInitiated CoverageUnderperform
8/14/2022Jefferies Financial GroupUpgradeHold ➝ Buy
3/8/2021The Goldman Sachs GroupUpgradeNeutral ➝ Buy
6/8/2020Jefferies Financial GroupDowngradeBuy ➝ Hold
12/9/2019Jefferies Financial GroupInitiated CoverageBuy
(Data available from 4/24/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 5 negative mentions
  • 5 very negative mentions
Mentions as of
9/27/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 4 very negative mentions
Mentions as of
10/27/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/26/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/25/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
2/24/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Daiichi Sankyo logo
Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.
Read More

Today's Range

Now: $30.50
Low: $30.16
High: $30.65

50 Day Range

MA: $31.85
Low: $29.15
High: $34.22

52 Week Range

Now: $30.50
Low: $23.72
High: $37.57

Volume

91,108 shs

Average Volume

133,512 shs

Market Capitalization

N/A

P/E Ratio

0.27

Dividend Yield

3.12%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Daiichi Sankyo?

The following Wall Street analysts have issued research reports on Daiichi Sankyo in the last year: Jefferies Financial Group Inc., and Sanford C. Bernstein.
View the latest analyst ratings for DSNKY.

What is the current price target for Daiichi Sankyo?

0 Wall Street analysts have set twelve-month price targets for Daiichi Sankyo in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Daiichi Sankyo in the next year.
View the latest price targets for DSNKY.

What is the current consensus analyst rating for Daiichi Sankyo?

Daiichi Sankyo currently has 1 sell rating and 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for DSNKY.

What other companies compete with Daiichi Sankyo?

Other companies that are similar to Daiichi Sankyo include AstraZeneca, Cosmo Pharmaceuticals, CSPC Pharmaceutical Group, Dechra Pharmaceuticals and JCR Pharmaceuticals. Learn More about companies similar to Daiichi Sankyo.

How do I contact Daiichi Sankyo's investor relations team?

Daiichi Sankyo's physical mailing address is Daiichi Sankyo Bldg. A/B Kan, Chuo Ku, Tokyo To 103-8426. The company's listed phone number is (136) 225-1111. The official website for Daiichi Sankyo is www.daiichisankyo.com. Learn More about contacing Daiichi Sankyo investor relations.